MRI-derived extracellular volume as a biomarker of cancer therapy cardiotoxicity: systematic review and meta-analysis - Takeaways - MDSpire

MRI-derived extracellular volume as a biomarker of cancer therapy cardiotoxicity: systematic review and meta-analysis

  • By

  • Gianluca Folco

  • Caterina B. Monti

  • Moreno Zanardo

  • Francesco Silletta

  • Davide Capra

  • Francesco Secchi

  • Francesco Sardanelli

  • October 12, 2023

  • 0 min

Share

  • 1

    Cancer therapy can lead to significant cardiovascular complications, particularly non-reversible cardiotoxicity, affecting morbidity and mortality.

  • 2

    Current guidelines recommend assessing left ventricular ejection fraction and myocardial strain to detect cancer therapy-related cardiac dysfunction.

  • 3

    Extracellular volume (ECV) derived from MRI T1 mapping may serve as an emerging biomarker for early detection of myocardial changes due to cardiotoxicity.

  • 4

    Increased ECV correlates with myocardial edema or fibrosis, indicating potential cardiomyocyte death and allowing for timely therapeutic adjustments.

  • 5

    This systematic review aims to evaluate the role of MRI-derived ECV as a biomarker for cardiotoxicity in patients undergoing cancer therapy.

Original Source(s)

MRI-derived extracellular volume as a biomarker of cancer therapy cardiotoxicity: systematic review and meta-analysis

  • by Gianluca Folco, Caterina B. Monti, Moreno Zanardo, Francesco Silletta, Davide Capra, Francesco Secchi, Francesco Sardanelli

  • October 12, 2023

Related Content

The translational paradox of AI in hepatocellular carcinoma: from algorithmic over-engineering to real-world clinical utility

Polar-coordinated contour processing algorithm in optimizing SCART treatment volume

A case report and literature review on imaging manifestations of immature teratoma in fetal oral cavity with concurrent intracranial abnormalities